

**COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS**

(Currently amended claims showing deletions ~~by strikethrough~~ or ~~[[double brackets]]~~ and additions by underlining)

1 - 10 (canceled)

11 (previously presented): A human PTH analogue of the formula, [Cha<sup>7,11</sup>, des-Met<sup>8</sup>, Nle<sup>18</sup>, Tyr<sup>34</sup>]hPTH(1-34)NH<sub>2</sub> (SEQ ID NO:16), which selectively binds to the PTH2 receptor, or a pharmaceutically acceptable salt thereof.

12 - 51 (canceled)

52 (previously presented): A human PTH analogue which selectively binds to the PTH2 receptor, wherein said analogue is selected from the group consisting of

[Cha<sup>7,11</sup>, des-Met<sup>8</sup>, Nle<sup>18</sup>, Tyr<sup>34</sup>]hPTH(1-34)NH<sub>2</sub> (SEQ ID NO:16),

[Cha<sup>7,11</sup>, D-Nle<sup>8</sup>, des-Met<sup>18</sup>, Tyr<sup>34</sup>]hPTH(1-34)NH<sub>2</sub>, and

[Cha<sup>7,11</sup>, D-Nle<sup>8</sup>, Nle<sup>18</sup>, Tyr<sup>34</sup>]hPTH(1-34)NH<sub>2</sub>,

which selectively binds to the PTH2 receptor, or a pharmaceutically acceptable salt thereof.

53 (previously presented): A pharmaceutical composition comprising an analogue according to claim 52 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

54 (currently amended): A method of ~~treating a medical disorder that results from altered or excessive action of the PTH2 receptor, which comprises administering to a patient in need thereof an effective amount of an analogue according to claim 52, sufficient to~~ inhibiting the activation of the PTH2 receptor of said patient , which comprises contacting the PTH2 receptor with an analogue according to claim 52.

55 (currently amended):        A method of treating a medical disorder that results from altered or excessive action of the PTH2 receptor ~~according to claim 54~~ wherein said medical disorder is abnormal CNS functions[[,]] or abnormal pancreatic functions, divergence from normal mineral metabolism and homeostasis, male infertility, abnormal blood pressure or a hypothalamic disease , which comprises administering to a patient in need thereof an effective amount of an analogue according to claim 52, sufficient to inhibit the activation of the PTH2 receptor of said patient.